The review's central claim — that in vitro testicular systems complement but cannot replace in vivo risk assessment — is supported by specific, internally consistent case studies rather than speculation. In Sertoli–germ cell cocultures from 28-day-old rats, MEHP caused dose-dependent germ cell detachment (440% of control at 100 µM) while parent DEHP and 2-ethylhexanol were largely inactive, exposing a critical metabolic blind spot: cultures cannot hydrolyze DEHP to its active metabolite Gray & Beamand 1986. The same cocultures showed m-DNB toxicity at ~10⁻⁵ M, enhanced by glutathione depletion (DEM), pinpointing nitrosonitrobenzene as the proximate toxicant Lamb et al. 1993.
The strongest single example is the TOCP/SCOTP Leydig–Sertoli coculture: Leydig cells metabolize TOCP to SCOTP, which then damages Sertoli cell nonspecific esterase — a toxicity invisible in Sertoli-only cultures Lamb et al. 1993. This is a rigorous demonstration of why monoculture screening systematically misses metabolic-activation toxicants.
The authors candidly acknowledge loss of spermatogenic staging, paracrine signaling, and inability to model spermiation; they also note primary cultures have limited lifespan and immortal lines are functionally abnormal. However, three limitations go under-addressed. First, all systems derive from immature rat tissue — 28- or 18-day-old donors — yet no cross-species or adult-tissue validation data are presented, leaving human extrapolation purely assumptive Lamb et al. 1993. Second, the review contains no quantitative validation matrix (sensitivity/specificity of in vitro→in vivo prediction across chemical classes); the phthalate concordance is a single-class anecdote. Third, subsequent work confirms these warnings: immortalized lines differ from primary cells — doxorubicin EC50 differed ~47-fold between rat spermatogonia (10.34 µM) and immature Sertoli (0.22 µM) lines, with antioxidants failing to protect — reinforcing that cell-line choice dominates outcomes Boisvert et al. 2018. Later 3D coculture improvements (KSR-supplemented, BPA-validated) partially address the architectural deficit the review flagged Shi et al. 2017.
Bottom line (confidence: high for descriptive claims; moderate for predictive value): the paper's framework is logically sound and mechanistically well-supported by its cited data, but it is an expert position piece, not a validated predictive platform — a distinction the authors themselves largely maintain. What would change this conclusion: a validated in vitro system reproducing spermiation and DEHP-class metabolic activation without animal tissue donors.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.